Israel - Hebräisch - Ministry of Health

dexcel pharma technologies ltd - atorvastatin as calcium - טבליה - atorvastatin as calcium 10 mg - atorvastatin - atorvastatin - litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. litorva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

Israel - Hebräisch - Ministry of Health

dexcel pharma technologies ltd - atorvastatin as calcium - טבליה - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. litorva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

Israel - Hebräisch - Ministry of Health

dexcel pharma technologies ltd - atorvastatin as calcium - טבליה - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. litorva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

Israel - Hebräisch - Ministry of Health

dexcel pharma technologies ltd - atorvastatin as calcium - טבליה - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. litorva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) :atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

Israel - Hebräisch - Ministry of Health

dexcel pharma technologies ltd - atorvastatin as calcium - טבליה - atorvastatin as calcium 80 mg - atorvastatin - atorvastatin - litorva is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. litorva is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) :atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190

Israel - Hebräisch - Ministry of Health

dexcel ltd, israel - desogestrel; ethinylestradiol - טבליה - ethinylestradiol 0.02 mg; desogestrel 0.15 mg - ethinylestradiol - ethinylestradiol - contraceptive.

Israel - Hebräisch - Ministry of Health

dexcel ltd, israel - ethinylestradiol; gestodene - טבליה - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - contraceptive.

Israel - Hebräisch - Ministry of Health

dexcel ltd, israel - ethinylestradiol; gestodene - טבליה - ethinylestradiol 0.02 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - contraceptive.

Israel - Hebräisch - Ministry of Health

dexcel ltd, israel - clarithromycin - קפליות - clarithromycin 250 mg - clarithromycin - clarithromycin - klaridex is indicated in the treatment of infections caused by one or more susceptible organisms. indications include: lower respiratory tract infections, for example, acute and chronic bronchitis and pneumonia. upper respiratory tract infections, for example, sinusitis and pharyngitis. klaridex is appropriate for initial therapy in community acquired respiratory infections and has been shown to be active in vitro against common and atypical respiratory pathogens as listed in the microbiology section. klaridex is also indicated in skin and soft tissue infections of mild to moderate severity. klaridex is also indicated in combination with proton pump inhibitor for the eradication of h. pylori in patients with proven duodenal ulcer. treatment of mycobacterium avium complex infection in aids patients.

Israel - Hebräisch - Ministry of Health

dexcel ltd, israel - ofloxacin - קפליות - ofloxacin 200 mg - ofloxacin - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as: upper and lower urinary tract infections, lower respiratory tract infections uncomplicated urethral and cervical gonorrhoea, non-gonococcal urethritis and cervicitis, skin and soft tissue infections.